

## Indoco Remedies receives US FDA nod for Lacosamide Oral Solution

**Agencies**

**Mumbai**

Indoco Remedies Ltd announced final approval of the Company's Abbreviated New Drug Application (ANDA) for Lacosamide Oral Solution USP, 10 mg/mL, to market, a generic equivalent to the reference listed drug (RLD), Vimpat Oral Solution, 10 mg/mL, of UCB, Inc. (UCB), from USFDA.

Lacosamide Oral Solution USP, 10 mg/mL, is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat Oral Solution, 10

mg/mL, of UCB, Inc. (UCB) and is manufactured in Verna.

Lacosamide Oral solution is used to treat partial onset seizures and primary generalized tonic-clonic seizures in adults and children with epilepsy who are at least 4 years old.

Commenting on the achievement, Aditi Panandikar, Managing Director said, "We are excited about the ANDA approval for Lacosamide Oral Solution USP, 10 mg/mL. This approval further reinforces our commitment to delivering high-quality healthcare to patients worldwide."